Show simple item record

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorFornaguera, Cristina
dc.contributor.authorGuerra-Rebollo, Marta
dc.contributor.authorLázaro, Miguel Ángel
dc.contributor.authorCascante, Anna
dc.contributor.authorRubio, Nuria
dc.contributor.authorBlanco, Jeronimo
dc.contributor.authorBorrós, Salvador
dc.date.accessioned2025-06-19T14:42:36Z
dc.date.available2025-06-19T14:42:36Z
dc.date.issued2019-09-02
dc.identifier.issn2192-2659ca
dc.identifier.urihttp://hdl.handle.net/20.500.14342/5327
dc.description.abstractOne of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties.ca
dc.format.extent16 p.ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofAdvanced healthcare materials, 2021;8(19):e1900849ca
dc.rights© Wiley. Tots els drets reservatsca
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.otherM-PBAE nanoparticlesca
dc.subject.otherliver retargetingca
dc.subject.otherprotein coronaca
dc.subject.otherretinolca
dc.titleIn Vivo Retargeting of Poly(beta aminoester) (OM-PBAE) Nanoparticles is Influenced by Protein Coronaca
dc.typeinfo:eu-repo/semantics/articleca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.terms12 mesosca
dc.subject.udc54ca
dc.identifier.doihttps://doi.org/10.1002/adhm.201900849ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO i FEDER/PN I+D/RTC-2015-3751-1ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO i FEDER/PN I+D/SAF2015-64927-C2-1-Rca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO i FEDER/PN I+D/SAF2015-64927-C2-2-Rca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/PN I+D/Torres Quevedo 2015ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/SUR del DEC/SGR/SGR 2017 1559ca
dc.description.versioninfo:eu-repo/semantics/acceptedVersionca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© Wiley. Tots els drets reservats
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint